Market Exclusive

Analyst Activity – HC Wainwright Reiterates Buy on CymaBay Therapeutics (NASDAQ:CBAY)

Analyst Ratings For CymaBay Therapeutics (NASDAQ:CBAY)

Today, HC Wainwright reiterated its Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) with a price target of $18.00.

Some recent analyst ratings include

Recent Insider Trading Activity For CymaBay Therapeutics (NASDAQ:CBAY)
CymaBay Therapeutics (NASDAQ:CBAY) has insider ownership of 15.10% and institutional ownership of 69.12%.

Recent Trading Activity for CymaBay Therapeutics (NASDAQ:CBAY)
Shares of CymaBay Therapeutics closed the previous trading session at 11.24 up +0.52 4.80% with 10.859999656677246 shares trading hands.

Exit mobile version